In this episode of "The Top Line," Fierce Biotech's Annalee Armstrong engages in a conversation with Howard Fillit, M.D., an expert in the field of Alzheimer's research and the co-founder and chief science officer at the Alzheimer's Drug Discovery Foundation.

They delve into the pioneering work being done in Alzheimer's research, discuss the latest breakthroughs, and explore the ongoing efforts to combat this complex disease.

To learn more about the topics in this episode: 

• With full Alzheimer's approval in hand, Eisai and Biogen kick off Leqembi's launch in earnest

• Eisai, Biogen's Leqembi may face rollout hurdles now, but experts still like the Alzheimer's drug

• Experimental Alzheimer's molecule improves cognition in mice by tamping down on inflammation

• Voyager Therapeutics adds anti-amyloid gene therapy to Alzheimer's pipeline

• Acumen's stock surges as early Alzheimer's data suggest next-gen Leqembi rival is active

See omnystudio.com/listener for privacy information.

“Essentially, this allows our clinical researchers to improve the chances of success for the trial leading to faster, more efficient drug development… Ultimately, this is going to benefit patients.”

Greg Lever is speaking about the use of flexible modeling to allow real-time changes to be made to clinical trial design and processes. 

As a Director within the IQVIA Applied Data Science Center, and with over a dozen years of experience in the field, Greg knows the importance of data and advanced analytics in generating accurate patient insights to underpin key trial decision-making.

By making clinical trials more patient friendly, he states, the more likely it is that research organizations will be able to attract and retain the participants they need to bring life-saving treatments to patients.

In this podcast, Greg outlines how modeling can be used to enhance the entire patient journey, from the initial giving of informed consent right through to the trial’s close.

Host: Julia Douthart

Producer: Matt Rickman

Sponsored by IQVIA

See omnystudio.com/listener for privacy information.

In this episode of "The Top Line," we delve into the uncharted territory that pharma marketers face, from harnessing AI's potential to navigating the Inflation Reduction Act. Ayla Ellison, editor-in-chief of Fierce Life Sciences and Healthcare, engages with three industry experts to unravel the opportunities and challenges that lie ahead.

In the first segment, Robert Allen, the leader behind engagement and channel planning for U.S. Oncology at Bristol Myers Squibb, shares his insights into strategic planning for customer engagement and channel strategies. Next, Terry Terifay, the Chief Commercial Officer at Azurity Pharmaceuticals, offers a glimpse into what the future holds for the industry. In the third segment, Dorothy Gemmel, the Chief Commercial Officer of GoodRx, shares the projects she's excited about and her biggest piece of advice for others in the industry."

To learn more about the topics in this episode: 

• Will Big Pharma engage in Medicare price negotiations? Merck, AZ and BMS say they will

• Providers can now see patients' insurance coverage in GoodRx's cost comparison tool

• Bristol Myers banks on 25-plus label expansions to help weather IRA, Revlimid generics and more

• GoodRx, Walgreens team to lower prices for 200 drugs

• Fierce Pharma unveils the winners of the 5th annual creativity contest for outstanding marketing campaigns

See omnystudio.com/listener for privacy information.

AstraZeneca has made several news headlines for its environmental sustainability pledges, including deals for renewable natural gas and a commitment to plant hundreds of millions of trees.

In this episode of "The Top Line," Fierce Pharma's Eric Sagonowksy talks with Pam Cheng, the AstraZeneca executive who is playing a key role in driving the company's sustainability ambitions.

To learn more about the topics in this episode: 

• Fellowship of the green: AstraZeneca, Samsung, GSK and more unite to slash greenhouse gas emissions

• AstraZeneca sows $400M investment in push to plant 200M trees by 2030

• From farm to pharma: AstraZeneca inks renewable natural gas pact to shrink environmental footprint

See omnystudio.com/listener for privacy information.

In this episode of "The Top Line," Annalee Armstrong and Gabrielle Masson shine a spotlight on some of the most promising companies in the biotech world. Additionally, you'll have the opportunity to hear from Kevin Dunleavy as he engages in a conversation with Ray Pressburger from Accenture, discussing drug commercialization and the models that are proving to be the most effective.

See omnystudio.com/listener for privacy information.

In this podcast interview, Dan Fisher, managing director and practice lead for IPM.ai, a division of Real Chemistry, explains how weekly data from 300 million patients can help brands assess a patient population, accelerate clinical trial recruitment, and optimize commercial outcomes.

Machine learning and artificial intelligence have emerged as key technologies for stitching together medical events and then predicting a diagnosis, even for conditions that are so rare no ICD-10 code exists. Once a de-identified rare or specialty disease patient is uncovered, IPM.ai enables clients to reach their top physicians directly, so they can prescribe a treatment-appropriate therapy or recommend a clinical trial. 

Fisher also discusses how IPM.ai works in cooperation with its sister organization, Swoop, to help reach and activate patient and physician audiences through healthcare advertising and a next best action engagement model, including for rare and specialty disorders.

Ai is an outstanding tool to help advance medical and business aspirations.

See omnystudio.com/listener for privacy information.

In this episode of "The Top Line," our Fierce reporters tackle topics like the trends we saw at Cannes Lions, the cancer drug shortage, and the top compensated CEOs in the industry. 

To learn more about the topics in this episode:

• National cancer group reports widespread chemo shortages, calls on government and industry to help resolve them
• FDA to allow temporary overseas production to shore up supplies of chemo drug
• FDA can't solve drug shortages on its own, agency's oncology chief says
• Play it loud: Cannes winner pitches sound therapy as extra tool in arsenal against cancer
• How Eversana roared back from rejection to craft Cannes-winning campaign hospitals couldn't ignore
• In a year of turnover, Seagen doled out $126M to a trio of CEOs
• The 15 highest paid pharma CEOs of 2021
• UPDATED: Moderna CEO Stéphane Bancel earned $19.4M in 2022 but made much more in stock sales

"The Top Line" and "Podnosis" are produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.

In this episode of "The Top Line," Teresa Carey talks with Dr. Sebastian Ocklenburg, Department of Psychology at MSH Medical School Hamburg, Germany, about how significant left-handedness is to clinical research. It is International Left-Hander's Day, so we dive deep into understanding brain hemisphere asymmetry and its significance in the context of neurodevelopmental and psychiatric disorders.

"The Top Line" and "Podnosis" are produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.

In this episode of "The Top Line," Zoey Becker talks with Dr. Andrew Norden, Chief Medical Officer at OncoHealth, about the ongoing chemotherapy shortage sweeping the nation and what oncologists and health insurance companies can do to best support patients amidst these supply chain issues.

We also cover the a single-injection treatment for sickle cell disease, battery-powered gene therapy, and the rest of the week's headlines. 

To learn more about the topics in this episode:

• National cancer group reports widespread chemo shortages, calls on government and industry to help resolve them
• FDA to allow temporary overseas production to shore up supplies of chemo drug
• FDA can't solve drug shortages on its own, agency's oncology chief says
• FDA links 4 deaths to recalled Abiomed Impella pumps after TAVR collisions
• Quest launches blood test for Alzheimer's disease aimed at general consumers
• One injection to cure sickle cell? Researchers give it a shot with new mRNA gene therapy
• With 3 AA batteries and 2 acupuncture needles, a device controls gene expression in live mice
  

"The Top Line" and "Podnosis" are produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.

In this episode of 'The Top Line' we reply an important show from April 28, 2023 regarding Narcan. 

On March 29th, the FDA approved the Narcan nasal spray for over-the-counter sales. It is the first naloxone product approved for use without a prescription. In this episode of The Top Line, Fierce Pharma staff writer Fraiser Kansteiner launches a mini-series to explore what that means for the opioid epidemic. The series will tackle questions about using the product, its accessibility and whether the move will save lives.

To learn more about the topics in this episode: 

• Emergent makes history with first FDA nod for over-the-counter naloxone
• Teva, Sandoz have launched Narcan generics, but Emergent's branded option should still thrive: analysts
• Adapt tests ads urging opioid users' loved ones to stock Narcan at home
• Eyeing $1B in annual sales, Emergent BioSolutions to buy Narcan maker Adapt for $735M
• Ahead of next month's FDA decision, Emergent aces AdComm for over-the-counter Narcan nod

The Top Line is produced by senior podcast producer Teresa Carey. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.

See omnystudio.com/listener for privacy information.